11:04 AM EDT, 07/02/2024 (MT Newswires) -- Immuron ( IMRN ) said Tuesday it has requested a pre-investigational new drug application meeting with the US Food and Drug Administration for IMM-529, a potential adjunctive therapy to treat Clostridioides difficile infection that affects the colon.
Shares of the company were up 3.7% in recent Tuesday trading.
Price: 2.26, Change: +0.08, Percent Change: +3.67